Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15202674 | 0.92 | HPGD (0.45) | RAB9AHPGDNPSR1GAAL3MBTL1 | |
| SCHEMBL20143804 | 0.89 | RAB9A (0.48) | RAB9AHPGDNPSR1GAAL3MBTL1 | |
| SCHEMBL24530130 | 0.78 | HPGD (0.53) | RAB9AHPGDNPSR1L3MBTL1NPC1 | |
| SCHEMBL8385954 | 0.76 | RAB9A (0.56) | RAB9AHPGDNPSR1GAAL3MBTL1 | |
| SCHEMBL38655243 | 0.75 | RAB9A (0.55) | RAB9AHPGDNPSR1GAAL3MBTL1 | |
| SCHEMBL29642608 | 0.74 | HPGD (0.51) | RAB9AHPGDNPSR1GAAL3MBTL1 | |
| SCHEMBL5018589 | 0.73 | HPGD (0.58) | RAB9AHPGDNPSR1GAANPC1 | |
| SCHEMBL12459480 | 0.73 | L3MBTL1 (0.58) | RAB9AHPGDNPSR1GAAL3MBTL1 | |
| SCHEMBL10062194 | 0.73 | HPGD (0.57) | RAB9AHPGDNPSR1GAAL3MBTL1 | |
| SCHEMBL10107892 | 0.73 | CASP3 (0.44) | HPGDNPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11193126-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-9970005-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11193126-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SNRPE, AGO2, SIN3A | RAB9A 1826/4885HPGD 3314/4885NPSR1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.